Protection for medication-induced hearing loss: the state of the science

Abstract

Objective: This review will summarise the current state of development of pharmaceutical interventions (prevention or treatment) for medication-induced ototoxicity.

Design: Currently published literature was reviewed using PubMed and ClinicalTrials.gov to summarise the current state of the science. Details on the stage of development in the market pipeline are provided, along with evidence for clinical safety and efficacy reported.

Study sample: This review includes reports from 44 articles and clinical trial reports regarding agents in clinical or preclinical trials, having reached approved Investigational New Drug status with the Federal Drug Administration.

Results: Vitamins and antioxidants are the most common agents currently evaluated for drug-induced ototoxicity intervention by targeting the oxidative stress pathway that leads to cochlear cell death and hearing loss. However, other strategies, including steroid treatment and reduction of ototoxic properties of the primary drugs, are discussed.

Conclusions: Retention of hearing during and after a life threatening illness is a major quality-of-life issue for patients receiving ototoxic drugs and their families. The agents discussed herein, while not mature enough at this point, offer great promise towards that goal. This review will provide a knowledge base for hearing providers to inquiries about such options from patients and interdisciplinary care teams alike.

Keywords:

• Ototoxicity
• hearing loss
• pharmaceutical
• drugs
• treatment
• prevention

Acknowledgements

The authors would like to thank the special issue editorial committee for inviting this article into the “Ototoxicity: Special Topics in Clinical Monitoring” collection. Additionally, the support and encouragement of the DOD Hearing Center of Excellence (HCE) and the HCE Pharmaceutical Interventions for Hearing Loss (PIHL) Working Group which brought this edition about. Finally, the authors would like to acknowledge and thank Melanie Halford for her copy-editing support and Mrs. Nicole Larionova for her support with the literature search.

Disclosure statement

The authors have no financial interests to disclose. Dr. Campbell’s previous financial interest in d-methionine has since dissolved.